Samsung Securities noted on the 22nd that with the reorganization of its portfolio centered on high-yield products, long-term growth is expected for Celltrion. The target stock price was raised from 210,000 won to 220,000 won, while maintaining an investment opinion of 'buy.'
Celltrion's consolidated revenue for the second quarter of this year is expected to be 961.5 billion won, with an operating profit of 242.5 billion won. This is an increase of 9.9% and 234.5%, respectively, compared to the same period last year.
The improvement in Celltrion's profitability is due to the sharp growth of high-yield new products like Remsima SC and Jimpentra, as well as the increasing revenue share of highly profitable products. Existing products maintained stable sales despite base effects and inventory pressures. Cost reductions in production were also achieved by switching from outsourcing the production of raw pharmaceuticals to in-house production starting from the second quarter.
Seo Geun-hee, a researcher at Samsung Securities, said, 'Total revenue for this year is expected to be 4.2455 trillion won, with an operating profit of 1.2319 trillion won.' He added, 'Four new items are scheduled to be launched in the second half, and we expect growth momentum to continue due to improvements in cost ratios and reductions in selling, general and administrative expenses.'